MedTrace Logo

Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?

NCT02236624 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-04-19

No results posted yet for this study

Summary

The purpose of the present study is to test the hypothesis that aerobic training can reduce flu-like symptoms following interferon beta 1a injections in patients with Multiple Sclerosis.

A secondary purpose is to evaluate whether or not changes in circulating cytokines provide a mechanism that can explain a potential positive effect.

Conditions

Interventions

BEHAVIORAL

Aerobic exercise

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • MS-Clinic of Southern Jutland

    collaborator UNKNOWN

  • MS-Clinic Viborg

    collaborator UNKNOWN

  • MS-Clinic Odense

    collaborator UNKNOWN

  • Biogen

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Martin Langeskov-Christensen, MSc · Sport Science, Department of Public Health, Aarhus University

  • Ulrik Dalgas, PhD · Sport Science, Department of Public Health, Aarhus University

  • Egon Stenager, Dr.med. · MS-Clinic of Southern Jutland (Sønderborg, Vejle, Esbjerg), Department of Neurology, Sønderborg, Denmark and Institute of Regional Health Services, University of Southern Denmark.

  • Thor Petersen, Dr.med. · MS-Clinic Aarhus, Department of Neurology, Aarhus University Hospital, Denmark

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-02-29
Completion
2016-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236624 on ClinicalTrials.gov